Literature DB >> 26202109

Systematic Evaluation of Different Nucleic Acid Amplification Assays for Cytomegalovirus Detection: Feasibility of Blood Donor Screening.

T Vollmer1, C Knabbe2, J Dreier2.   

Abstract

Acute primary cytomegalovirus (CMV) infections, which commonly occur asymptomatically among blood donors, represent a significant risk for serious morbidity in immunocompromised patients (a major group of transfusion recipients). We implemented a routine CMV pool screening procedure for plasma for the identification of CMV DNA-positive donors, and we evaluated the sensitivities and performance of different CMV DNA amplification systems. Minipools (MPs) of samples from 18,405 individual donors (54,451 donations) were screened for CMV DNA using the RealStar CMV PCR assay (Altona Diagnostic Technologies), with a minimum detection limit of 11.14 IU/ml. DNA was extracted with a high-volume protocol (4.8 ml, Chemagic Viral 5K kit; PerkinElmer) for blood donor pool screening (MP-nucleic acid testing [NAT]) and with the Nuclisens easyMAG system (0.5 ml; bioMérieux) for individual donation (ID)-NAT. In total, six CMV DNA-positive donors (0.03%) were identified by routine CMV screening, with DNA concentrations ranging from 4.35 × 10(2) to 4.30 × 10(3) IU/ml. Five donors already showed seroconversion and detectable IgA, IgM, and/or IgG antibody titers (IgA(+)/IgM(+)/IgG(-) or IgA(+)/IgM(+)/IgG(+)), and one donor showed no CMV-specific antibodies. Comparison of three commercial assays, i.e., the RealStar CMV PCR kit, the Sentosa SA CMV quantitative PCR kit (Vela Diagnostics), and the CMV R-gene PCR kit (bioMérieux), for MP-NAT and ID-NAT showed comparably good analytical sensitivities, ranging from 10.23 to 11.14 IU/ml (MP-NAT) or from 37.66 to 57.94 IU/ml (ID-NAT). The clinical relevance of transfusion-associated CMV infections requires further investigation, and the evaluated methods present powerful basic tools providing sensitive possibilities for viral testing. The application of CMV MP-NAT facilitated the identification of one donor with a window-phase donation during acute primary CMV infection.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26202109      PMCID: PMC4572558          DOI: 10.1128/JCM.01091-15

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  28 in total

1.  Asymptomatic primary cytomegalovirus infection: virologic and immunologic features.

Authors:  F Zanghellini; S B Boppana; V C Emery; P D Griffiths; R F Pass
Journal:  J Infect Dis       Date:  1999-09       Impact factor: 5.226

2.  Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation.

Authors:  V C Emery; C A Sabin; A V Cope; D Gor; A F Hassan-Walker; P D Griffiths
Journal:  Lancet       Date:  2000-06-10       Impact factor: 79.321

3.  Multicenter evaluation of PCR methods for detecting CMV DNA in blood donors.

Authors:  J D Roback; C D Hillyer; W L Drew; M E Laycock; J Luka; E S Mocarski; B Slobedman; J W Smith; C Soderberg-Naucler; D S Todd; S Woxenius; M P Busch
Journal:  Transfusion       Date:  2001-10       Impact factor: 3.157

4.  The effect of leukocyte-reduction method on the amount of human cytomegalovirus in blood products: a comparison of apheresis and filtration methods.

Authors:  L J Dumont; J Luka; T VandenBroeke; P Whitley; D R Ambruso; M D Elfath
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

5.  CMV DNA is rarely detected in healthy blood donors using validated PCR assays.

Authors:  John D Roback; W Lawrence Drew; Megan E Laycock; Deborah Todd; Christopher D Hillyer; Michael P Busch
Journal:  Transfusion       Date:  2003-03       Impact factor: 3.157

6.  Frequency and duration of plasma CMV viremia in seroconverting blood donors and recipients.

Authors:  W Lawrence Drew; Gary Tegtmeier; Harvey J Alter; Megan E Laycock; Richard C Miner; Michael P Busch
Journal:  Transfusion       Date:  2003-03       Impact factor: 3.157

7.  High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion.

Authors:  Malte Ziemann; Sabine Krueger; Andrea B Maier; Alexander Unmack; Siegfried Goerg; Holger Hennig
Journal:  Transfusion       Date:  2007-11       Impact factor: 3.157

8.  Cytomegalovirus as a cause of very late interstitial pneumonia after bone marrow transplantation.

Authors:  C R de Medeiros; V A Moreira; R Pasquini
Journal:  Bone Marrow Transplant       Date:  2000-08       Impact factor: 5.483

9.  The impact of donor cytomegalovirus DNA on transfusion strategies for at-risk patients.

Authors:  Malte Ziemann; David Juhl; Siegfried Görg; Holger Hennig
Journal:  Transfusion       Date:  2013-04-15       Impact factor: 3.157

10.  The blood donor: detection and magnitude of cytomegalovirus carrier states and the prevalence of cytomegalovirus antibody.

Authors:  W L Bayer; G E Tegtmeier
Journal:  Yale J Biol Med       Date:  1976-03
View more
  1 in total

1.  Transfusion-transmitted cytomegalovirus: behaviour of cell-free virus during blood component processing. A study on the safety of labile blood components in Switzerland.

Authors:  Sophie Voruz; Peter Gowland; Claudia Eyer; Nadja Widmer; Mélanie Abonnenc; Michel Prudent; Stavroula Masouridi-Levrat; Michel A Duchosal; Christoph Niederhauser
Journal:  Blood Transfus       Date:  2020-02-28       Impact factor: 3.443

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.